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Cancer is threatening, and understandably many patients are
anxious in response to that threat. Unfortunately that anxiety
sometimes becomes a clinically important problem in its own
right, and cancer care professionals will often be responsible for its
initial recognition and management. Anxiety does not feature
much in the standard oncology literature. In this article we there-
fore review recent research into anxiety complicating cancer and
other physical illnesses.
THE NATURE OF ABNORMAL ANXIETY IN
CANCER
Anxiety produces a number of typical symptoms and signs.
Symptoms of autonomic over-activity include palpitation and
sweating. Anxious behaviours such as restlessness and
reassurance-seeking are a feature. Changes in thinking include
apprehension, worry and poor concentration, and physical symp-
toms such as muscle tension or fatigue may occur.
Since anxiety is a frequent response to threat, it is found in all
clinical populations. It can be adaptive, but in certain circum-
stances it becomes maladaptive or morbid. Such pathological
anxiety is identified by:
1. Being out of proportion to the level of threat
2. Persistence or deterioration without intervention
3. A level of symptoms which are unacceptable regardless of the
level of threat (these include recurring panic attacks, severe
physical symptoms, and abnormal beliefs such as thoughts of
sudden death)
4. A disruption of usual or desirable functioning:
These characteristics are used to define anxiety disorders in the
common diagnostic systems employed in psychiatry: the World
Health Organization’s International Classification of Disorders
(ICD–10) and the American Psychiatric Association’s Diagnostic
and Statistical Manual (DSM-IV). In practice, these criteria may
be difficult to apply to cancer patients.
It is difficult to judge when anxiety is disproportionate to the
threat of cancer, since the disease is always associated with some
real threat. The level of anxiety must be judged against the pro-
ximity of threat. For example, it is normal to experience con-
siderable anxiety for a period of 7–10 days after receiving bad
news (Holland, 1989), but as the degree of real threat varies
throughout the history of the cancer, so therefore do levels of
normal anxiety. In certain situations too little anxiety may be as
problematic for adaptation as too much, and so while thoughts
about recurrence and death will be natural early after diagnosis or
relapse, they are not so during a long remission, with the point of
transition being difficult to ascertain.
While the duration of symptoms is usually important in distin-
guishing abnormal anxiety the natural history of anxiety in
oncology is uncertain, so this criterion is also difficult to apply.
This may be because a range of definitions of abnormal anxiety
have been used, and because anxiety is often labile and situational,
making the onset of an episode difficult to define. Persistent
anxiety may be identified quite early after diagnosis of cancer:
anxiety which persists only 3 weeks after a ‘bad-news consulta-
tion’ is highly predictive of anxiety 6 months later (Nordin and
Glimelius, 1999). The prevalence of anxiety problems after a
cancer diagnosis falls over the following years (Fallowfield et al,
1994), but may not return to population levels even with curative
treatment (Loge et al, 1997).
Unacceptable symptoms and disruption in functioning are often
at least as useful in defining pathological anxiety in a cancer
patient as other criteria. Intrusive and unpleasant anxious thoughts,
often involving recurrence of disease, death, or disability, can
cause considerable disruption in concentration, decision-making,
sleep, and social functioning. Consequent behaviours, such as
avoidance, repetitive checking of health, and seeking reassurance
for transient somatic symptoms, can be disruptive for the indi-
vidual and their family.
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doi: 10.1054/ bjoc.2000.1405, available online at http://www.idealibrary.com on Abnormal anxiety can be classified based upon its clinical
features. In the standardized diagnostic systems there are four
main types of anxiety disorder (Table 1). The anxious adjustment
disorder represents a quantitatively excessive response to a
stressful event. However, a single severe negative life-event also
increases the risk of generalized anxiety disorder. A diagnosis of
generalized anxiety disorder requires more symptoms than
anxious adjustment disorder, although degree of disruption is not 
a distinguishing feature. Adjustment disorders therefore take an
intermediate position between other anxiety disorders and normal
anxiety. The anxiety in panic disorder has specific features: it
builds up in a rapid crescendo, it occurs in many situations so
anticipatory avoidance is not feasible, and it is usually associated
with a rapid exit from the situation in which it occurs. By contrast
with these three disorders, phobic anxiety only occurs in specific
situations, that is, in the presence of provoking stimuli, so antici-
patory avoidance is common. In cancer care, phobias may arise in
relation to hospital and to treatments in particular.
Anxiety may also be present in association with depression. In
physically healthy populations mixed anxiety and depressive
disorders are commoner than anxiety disorders occurring alone
(Jenkins et al, 1998). Such an overlap also occurs in cancer
populations, and therefore it has been recommended that clini-
cians assessing anxiety always seek co-existent depression, as
treatment for depression may resolve the anxiety (Wise and
Rieck, 1993).
Distinctions between pathological and adaptive anxiety, and
between different forms of anxiety, are of some importance.
Anxiety in a setting of distress, not psychiatric disorder, may be
amenable to supportive care, and the response to specialized
therapy differs between the diagnoses (Ramirez, 1989).
EXTENT AND IMPACT OF ANXIETY IN CANCER
PATIENTS
The prevalence of anxiety disorders in the general population is
reported as between 3% and 16% in the UK (Jenkins et al, 1998).
The reported prevalence of anxiety problems in cancer patient
populations varies widely between studies (Table 2), but in
comparisons within the general population pathological anxiety is
commoner in people with cancer than in those without any chronic
medical condition (Wells et al, 1988).
In the general population, younger women are more prone to
anxiety (Jenkins et al, 1998). However age, gender, marital status,
social class and education are not associations consistently seen
with anxiety in cancer patient populations. Perhaps when the
stressor is more severe, degrees of susceptibility may become less
important (Noyes et al, 1998).
Anxiety certainly can cause disruption, and be detrimental to
quality of life. A pattern of association between anxiety and self-
reported quality of life, particularly impaired social functioning,
fatigue and physical impairment, has been demonstrated in cancer
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Table 1 The anxiety disorders
Diagnosis World Health Organization criteria Cardinal features
Somatic symptoms Symptom pattern Situation Response
Panic At least four of the following including one from a to d: A discrete episode Many Hurried exit
disorder a. Palpitation, pounding heart or accelerated heart rate of intense fear or situations
b. Sweating discomfort, with a
c. Trembling/shaking crescendo pattern,
d. Dry mouth (not due to medication) starts abruptly and
e. Difficulty in breathing reaches a
f. Feeling of choking maximum within a
g. Chest pain or discomfort few minutes
h. Nausea or abdominal discomfort
i. Feeling dizzy, unsteady, faint or light-headed
j. Feeling that objects are unreal or that the self is distant or not 
really there
k. Fear of losing of control, going crazy, passing out
l. Fear or dying
m. Hot flushes or cold chills
n. Numbness or tingling sensations
Anxious As for other anxiety disorders, but insufficient to fulfil criteria for those Onset of symptoms Not Not specific
adjustment within 1 month of specific
disorder an identifiable
psychosocial
stressor
Phobia As for panic disorder Not specific Specific Avoidance
Generalized As for panic disorder, with the following also included: A period of 6 Most Not specific
Anxiety o. Muscle tension or aches and pains months with situations
Disorder p. Restlessness and inability to relax prominent, tension,
q. Feeling keyed up, on edge or mentally tense worry and feelings
r. Sensation of difficulty swallowing/lump in the throat of apprehension
s. Exaggerated response to minor surprises/being startled about everyday 
t. Difficulty concentrating or ‘mind going blank’ because of anxiety  problems
or worry
u. Persistent irritability
v. Difficulty in getting to sleep because of worryingcare (Aass et al, 1997). Caution needs to be exercised in inter-
preting these associations, as there are several conflicting explana-
tions for them, as to both the causal direction of the association and
the explanation for the pattern.
The causal direction of this association might be that some
disease-related symptoms are more anxiety-provoking than others.
However, alternatively, physical symptoms identified in quality of
life questionnaires may be due to anxiety rather than directly to
cancer or its treatment. Forester et al (1993) illustrated that anxiety
can contribute to anorexia, nausea, vomiting and fatigue in cancer
patients, when they demonstrated reduction in these physical
symptoms after psychotherapy.
Reporting of experience is not like playing back a tape-
recording; individuals have to have noticed what took place, and to
recall it, in order to reconstruct events. In anxious individuals this
process may be systematically biased, favouring attention to, and
possibly recall of, threatening experiences (Mogg et al, 1995).
When we ask patients to assess their symptoms and functional
status, particularly under the duress of an outpatient appointment,
those problems which are threatening may be selectively reported.
Another perspective is that anxiety may influence the quantity
of all symptoms that are recalled. For example, anxiety is associ-
ated with increased tamoxifen side-effects during breast cancer
treatment, apparently due to the recall of more actual side-effects
(Cameron et al, 1998).
The relation of anxiety to reported quality of life is of impor-
tance, as responses which reflect situational anxiety present in the
outpatient clinic may not represent the patients’ problems at other
times.
Anxiety may also have consequences for the provision of cancer
care. Psychiatric illnesses including anxiety, when present with
physical illness, increase the resources used to manage that phys-
ical illness, independent of resource used in psychiatric care
(House, 1996). Discharge from hospital cancer care to general
practice is more difficult in the presence of anxiety (Thomas et al,
1997), perhaps because of greater severity of physical illness in
this group or due to reluctance from the anxious patient.
WHAT CAUSES ANXIETY — CANCER AS THREAT
The disease
The idea of cancer is threatening, such that experiments which
require anxiety-generating words may use the word cancer as a
stimulus (Mogg et al, 1995). Anxiety levels are high soon after the
onset of cancer symptoms, during investigation and diagnosis, but
many people adapt over time (Fallowfield et al, 1994).
Anxiety appears to increase as illness progresses, such that more
extensive disease is associated with higher prevalence of anxiety
in the majority of studies (Noyes et al, 1998). However, such
covariation of anxiety and progression of disease may not be found
when analysis is controlled for physical disability (Schag and
Heinrich, 1989; Aass et al, 1997).
As well as disability, other disease manifestations such as pain
are associated with anxiety, although the causal direction is uncer-
tain. For example, group therapy may improve breast cancer pain
the extent of the improvement correlating with anxiety reduction
(Spiegel and Bloom, 1983).
The treatment
Cancer treatment involves a mixture of positive and negative
implications, with unpleasantness and threat from the process and
the hope of relief from the illness or its symptoms working in
opposite directions.
In general, high levels of anxiety develop before surgery and
abate afterwards, implying that the threat of surgery is viewed as
short-term. Oncological surgery appears to be associated with a
similar pattern. When Thomas et al (1987) measured psycholog-
ical morbidity after colostomy, they found no difference in anxiety
between patients who had the operation for malignant or benign
disease. This suggests it is not the malignant element but the
surgery itself that is relevant.
Chemotherapy and radiotherapy are associated with anxiety but
the context is important. Toxicity of chemotherapy co-varies with
anxiety, in a multivariate analysis controlled for progression of
disease and performance status (Schag and Heinrich, 1989).
Toxicity can thus represent a threat at the time it is occurring.
However, for patients with inoperable lung cancer the highest level
of anxiety is seen in patients not receiving chemotherapy or radio-
therapy (Hughes, 1987); perhaps because no treatment is inter-
preted as meaning deterioration in health is unavoidable. In a
randomized controlled trial of adjuvant chemotherapy against
observation in early breast cancer, patients in the two arms had 
the same anxiety levels (Cassileth et al, 1986). In this setting,
chemotherapy appears not to cause more perceived threat than
observation, or alternatively both had the potential to be threat-
ening to some individuals.
Patients undergoing serial intracavitary radiotherapy for gynae-
cological cancer experience high levels of anxiety, beginning prior
to the intervention, but these do not rapidly dissipate or habituate
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Table 2 The prevalence of abnormal anxiety in observational studies of cancer patient
Reference Prevalence Comments
Lee et al, 1992 Anxiety ‘cases’: 17.8–6.5% over 12 months Sample: Breast cancer, n = 159
Fallowfield et al, 1994 Anxiety disorders: 17–23% over 36 months Sample: Breast cancer, n = 216
Harrison and Maguire, 1994 2.3% generalized anxiety disorder Sample: Mixed primaries, n = 520
4.2% adjustment disorder with anxious mood
Kissane et al, 1998 1.7% generalized anxiety disorder Sample: Breast cancer, n = 303
6.9% phobic disorder
1.3% panic disorder
3.9% adjustment disorder with anxious mood
The studies listed are restricted to those with sample sizes over 100, since 1990, where anxiety is measured by semi-structured interview,
using International Classification of Disease or Diagnostic and Statistical Manual criteriafor later treatments (Andersen et al, 1984). The threatening
element is persistent, possibly because of the serial element of the
therapy, or the intimate nature of the intervention. Patients ending
radiotherapy experience a rise in anxiety; perhaps the interpreta-
tion is the loss of a perceived protective effect (Holland, 1989).
Other specific elements of the cancer patients’ experience influ-
ence anxiety Magnetic resonance scans are associated with anxiety
in up to a third of patients, particularly those with prior history of
panic (Melendez and McCrank, 1993). It might be assumed that the
problem is the investigation, as the subject is highly enclosed. While
this may be the explanation, during CT scans the major concern of
patients is with the disease not the scan process (Peteet et al, 1992).
Each can be threatening, but not necessarily for the same reasons.
Anxiety symptoms in cancer care may be an organic phenom-
enon, often pharmacological. Some organic causes are well known,
such as corticosteroids. Others are less so, for example there 
can be an early rise in anxiety associated with the antidepressant
fluoxetine, and the adverse effects of biological therapies such as
interferon alpha include psychiatric syndromes (Trask et al, 2000).
While it is clear that cancer is a threat to future health and to life,
it is not a cause of disabling anxiety in the majority of patients. It
does not seem that particular parts of the process of illness, inves-
tigation and treatment are predictably making most patients
anxious. Instead it may be necessary to explore the interpretations
and meanings attached to events for the individual. This was
observed by Lazarus, who characterized patient responses to
illness in terms of the emotional elements of events; fear, anger, or
sadness, and the meaning of the cancer; its identity, time-course,
consequences, cause, and controllability (Lazarus, 1993). Both
these emotional and cognitive elements contribute to assessing the
threat. The meaning of an event may then be the crux of why an
individual is anxious, and that meaning may not be what is imme-
diately apparent to the clinician, and be specific to individual
patients and their circumstances.
THE MANAGEMENT OF ANXIETY WITHIN
ONCOLOGY
Often oncologists and cancer care nurses will be responsible for
the identification of patients who have problems with anxiety.
Screening has been used in an attempt to improve detection of
psychiatric morbidity, including anxiety. It is acceptable to
patients and amenable to some automation (Velikova et al, 1999).
There are various screening questionnaires (Table 3), each with
their individual advantages and disadvantages (Hall et al, 1999;
Trask et al, 2000). There is no brief screening questionnaire 
which specifically measures anxiety. The Hospital Anxiety and
Depression Scale, the General Health Questionnaire, and many
quality of life instruments include anxiety items, but it is uncertain
to what extent they distinguish anxiety from non-specific distress,
unless they are followed by clinical assessment. There are few
direct comparisons of the efficacy of these in the general oncology
outpatient population. Screening can be valuable however, and
there is a trend for greater efficacy of psychological interventions
in screened populations than for those not screened (Sheard and
Maguire, 1999).
Having identified that an individual has problems with anxiety,
there is a need to intervene either within cancer care or by referring
for specialist treatment. There are several pharmacological inter-
ventions of demonstrated efficacy (Table 4). There is a wide 
range of drug interventions available but have been few studies
comparing their efficacy in cancer patients, and therefore decisions
are often based upon the urgency for treatment effect to begin, clin-
ical experience with individual agents, and toxicity profiles. This
area has been recently reviewed (Kerrihard et al, 1999).
Psychological treatments for cancer patients with anxiety or
depression have recently been the subject of a meta-analysis of
published and unpublished studies (Sheard and Maguire, 1999).
This reiterated the effectiveness for anxious cancer patients of
individual and group therapies, and of educational interventions as
well as relaxation, when delivered by mental health specialists.
Notably there was no difference in effectiveness of such treatments
between patients with metastatic and those with better-prognosis
disease. However, treatments needed an experienced therapist and
were more likely to be beneficial the longer they took, which could
have substantial consequences for provision of services.
Involvement of a mental health professional is not a useful
option for many anxious cancer patients. The range of available
services is often limited, and depends upon the selection of cases
appropriate for referral. In addition, not all patients are prepared to
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Table 3 Some screening tools commonly used to assess anxiety by patient self-report
Measure Advantages to the oncologist Disadvantages to the oncologist
Hospital Anxiety and Excludes somatic symptoms of disease Used alone is poor at detecting depression. The
Depression Scale Brevity (14 items in all, 7 concerning anxiety) depression subscale missed at least 62% of cases
(Zigmond and Snaith, Widespread use in cancer and other physical with depression at interview (Hall et al, 1999)
1983) illnesses.
More effective than many other instruments: at a
cut-off of 7 the anxiety scale missed 28% of the
individuals with morbid anxiety at interview, and
21% of those without morbid anxiety were found to
have scores above the threshold (Hall et al, 1999).
Use as a screen and a measure longitudinally of
progress (Kissane et al, 1998; Fallowfield et al,
1994)
State-Trait Anxiety Specific to anxiety Used alone is not detecting depression
Inventory Use as a screen and a measure longitudinally Longer (20–40 items) than many self-report
(Spielberger, 1983) screening questionnaires
General Health Brevity (12-item version) Screening efficacy in oncology outpatients remains
Questionnaire, Excludes somatic symptoms of disease uncertain.
(Goldberg et al, 1997) Use as a screen and a measure longitudinallyaccept referral, and so there is a need for the management of many
of these problems to take place within cancer care.
Giving information is often the first step in helping anxious
patients. While information needs to be tailored to the wishes of
the individual (Leydon et al, 2000) many patients in the UK want
more information about their cancer. Poor or incomplete informa-
tion can generate mistrust of medical staff. Patients are not
deprived of hope by information; perhaps they still consider them-
selves within a group of individuals likely to respond to treatment
whatever their understanding of the odds of that happening.
Patients do not necessarily ask for the further information they
want, so many retain lay perceptions that are ‘worse than the facts’
(Fallowfield, 1997). Knowledge may therefore achieve reduction
in anxiety, when it is tailored to an understanding of the meaning
of events to the patient.
Patient choice in treatment appeared beneficial in early studies,
however when this work was repeated in a larger sample a benefit
was not demonstrated for choice. Instead those who adapted best
were patients under the care of surgeons who offer choice where
technically feasible, whether to that patient or not, and those who
were satisfied with the information received about the illness
and treatment. This points to the role of communication skills
(Fallowfield et al, 1994).
Effective communication skills are central to information
giving, with substantial correlation between anxiety and poor
communication with the medical team (Schag and Heinrich,
1989). Workshops encouraging open questioning, psycholog-
ical issues, empathy and summarizing, while discouraging reas-
surance, ‘advice mode’, and leading questions have achieved
enduring change and greater disclosure of patients’ psychosocial
problems (Maguire, 1995).
Over and above these general approaches the oncologist needs
to be alert to specific difficulties in communication with anxious
cancer patients.
Anxious individuals experience and report more symptoms
related to their cancer and its treatment than others. Oncologists
are often asked to reassure anxious patients that their experienced
symptoms are not due to worsening of the cancer. However, even
in the absence of progression of the cancer after appropriate
investigation, well-meaning simple reassurance may inadvertently
worsen anxiety. Anxiety may be temporarily reduced, such that it
may appear during the consultation that anxiety has been effec-
tively managed, but often it rapidly returns. The implication may
be that the cause of the anxiety is not removed by many consulta-
tions, although this is the aim (Lucock et al, 1997).
A cognitive model of this problem has been suggested, which
has the potential advantage of allowing oncologists to intervene
specifically to help some anxious patients. The model identifies a
group of beliefs and behaviours characteristic of patients who are
anxious about their health:
• Beliefs: Tending to interpret everyday bodily symptoms as
indicative of serious disease
• Concerns: Health worry and preoccupation, fear of serious
illness, and of death. This can be intrusive and difficult to
control
• Behaviours: Reassurance-seeking, including seeking medical
consultations.
While this model is derived from work on extreme levels of
psychological morbidity such as hypochondriasis, it applies in
general medical settings and general practice (Lucock et al, 1997;
Conroy et al, 1999). After a cancer diagnosis, patients learn to
monitor their bodies for symptoms of relapse, and interpret their
symptoms. Health anxiety may be seen as a maladaptive pattern of
such monitoring.
The anxious individual is highly vigilant to threatening stimuli,
but when they notice them they employ ‘quick-fix’ techniques to
reduce the emotion this causes (Lucock et al, 1997). Seeking
expert advice about non-specific symptoms when living with
cancer or a previously treated cancer is of course not necessarily
maladaptive. Reassurance-seeking behaviour is, however, mal-
adaptive if it is out of proportion to the symptoms present. It may
be so also if it becomes an enduring coping pattern, where reassur-
ance reduces the anxiety only temporarily and then reassurance-
seeking is used again, or increasingly, perpetuating the anxiety
rather than developing more constructive responses.
To intervene more effectively an oncologist may need a distinct
approach to improving communication with anxious cancer
Anxiety in cancer patients 1265
British Journal of Cancer (2000) 83(10), 1261–1267 © 2000 Cancer Research Campaign
Table 4 Pharmacological interventions in anxious cancer patients
Intervention Comments
Beta-blockers Help to control unpleasant palpitation and tremor, but not anxiety itself
Tricyclic antidepressant, such as imipramine Anxiolytic effect is slow in onset (weeks)
Not dependency inducing
Useful in panic disorder, or in anxiety with depression
Anticholinergic effects can be ameliorated by a low starting dose
Selective serotonin reuptake inhibitors, such as Less toxicity than tricyclic antidepressants, particularly anti-cholinergic effects
paroxetine
Short-acting benzodiazepine, such as alprazolam All benzodiazepines are potentially dependency inducing and therefore should only
be used to cover periods where an identified stressor will end after a short period
(days)
Rapid onset of effect, but problems may recur on withdrawal
Less likely than long-acting benzodiazepines to accumulate in liver disease
Long-acting benzodiazepine, such as diazepam Useful to manage recurrent symptoms after a course of short-acting
benzodiazepine
Neuroleptic, such as haloperidol Useful adjunct to benzodiazepines
Less respiratory depression than benzodiazepines
Not dependency inducing.
Avoid long-term use because of risk of tardive dyskinesia
From Kerrihard et al, 1999patients. They could go beyond eliciting symptoms and concerns
and offering reassurance, and discuss the patients’ interpretation
of their symptoms. They might discuss the nature of symptoms in
general, outlining and perhaps providing a simple checklist of
sinister and non-sinister problems, to provide education that the
patient could apply to reduce their own anxiety when future symp-
toms occur. This distinct approach has the potential to reduce the
anxiety of some cancer patients.
CONCLUSIONS
Morbid anxiety in the setting of cancer care can be a problem in its
own right. It can be difficult to use all the current research criteria
to define when anxiety is pathological, because they depend upon
a subjective judgement as to the extent of actual threat, and
rigorous studies defining the natural history of normal or adaptive
anxiety are incomplete. However, the presence of severe or disrup-
tive symptoms such as panic attacks can be diagnostic regardless
of context.
It can be helpful to determine which form of anxiety problem is
present for a specialist pharmacological or psychological interven-
tion, but this form of management is neither universally available,
nor acceptable to all patients. Oncologists may need to develop
their own approach to anxious patients. There are several sugges-
tions from the literature in this area:
1. It is helpful to explore the meaning patients attach to events.
These are the basis of the perceived threat for the individual,
and they may differ from the perceptions of clinicians.
2. Information and education are important in alleviating anxiety,
even if the situation is difficult, as fears are often based upon
incorrect information.
3. Communication can be particularly difficult with the anxious
patient. It may be helpful to avoid responding with simple
reassurance when the anxious patient raises a symptom. While
this may result in a short-term dissipation of anxiety in the
course of the consultation, it is often ineffective in durably
resolving the patients’ anxiety. Instead, eliciting concerns of
the patient beyond a symptom itself, exploring and correcting
the ways patients interpret the symptoms they experience, may
be more likely to enduringly reduce anxiety.
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